VivoSeq
Rare Disease

SMA

0

Pipeline Programs↗

9

Active Trials↗

13

Companies Involved↗

SMA is an early-stage landscape with 0 programs across 13 companies. The most active players are Merck & Co., Merz Pharmaceuticals GmbH, BioAegis Therapeutics Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalM

Merz Pharmaceuticals GmbH

0 programs

PreclinicalB

BioAegis Therapeutics Inc.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

71

clinical trials

Completed46 · 65%
Unknown status12 · 17%
Recruiting5 · 7%
Not yet recruiting3 · 4%
Terminated2 · 3%
Withdrawn2 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

71 trials

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Recruiting·SSt Vincent's Hospital, Sydney·Phase 2·NCT04925648·22 enrolled
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Recruiting·National Institute of Respiratory Diseases, Mexico·Phase 4·NCT06571942·128 enrolled
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Recruiting·Novartis logoNovartis·Phase 3·NCT05939414·450 enrolled
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Recruiting·—·Phase 1·NCT07054346·45 enrolled
Basal Plasma Lithium Levels and Suicidal Events
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT05409794·158 enrolled
GCC Agonist Signal in the Small Intestine
Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT05107219·43 enrolled
Plasma Beta-endorphin Levels and Suicidal Behavior
Not yet recruiting·UUniversity Hospital, Montpellier·N/A·NCT06291467·104 enrolled
Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07491367·20 enrolled
Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients
Not yet recruiting·—·Phase 2·NCT07441837·60 enrolled
A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects
Completed·MMerz Pharmaceuticals GmbH·Phase 1·NCT01109680·8 enrolled
Platelet-rich-plasma Treating Tennis Elbow
Completed·ZZimmer Biomet·N/A·NCT00757289·106 enrolled
Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot
Completed·—·Phase 4·NCT02742285·16 enrolled
CVN058 Effect on Mismatch Negativity in Schizophrenics
Completed·CCerevance Alpha, Inc.·Phase 1·NCT03669250·22 enrolled
Plasma CO2 Removal Due to CRRT and Its Influence on Indirect Calorimetry
Completed·UUniversitair Ziekenhuis Brussel·N/A·NCT03314363·10 enrolled
Plasma Oxalate in Patient With Short Bowel
Completed·HHospices Civils de Lyon·N/A·NCT04119765·47 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)